Market Research Logo

Global Gastric Cancer Market Report: 2016 Edition

Global Gastric Cancer Market Report: 2016 Edition

Cancer is a condition where an error or mutation in the cell’s DNA occurs, causing it to grow at a rapid rate. A cancer cell continues living while a normal cell would die, thus, accumulating to form a tumor that can break off and spread throughout the body. Gastric cancer is when such a condition occurs in the stomach and has the tendency to grow through the wall of the stomach to invade nearby organs including lymph nodes and lymph vessels. There are four types of cancers of the stomach namely, Adenocarcinoma, Lymphoma, Gastrointestinal stromal tumor (GIST), Carcinoid tumor and others such as squamous cell carcinoma, small cell carcinoma, and leiomyosarcomat that can start in the stomach, but are very rare.

The causes of stomach cancer are rather unclear in medical study; however, there is a strong correlation between a diet high in smoked, salted and pickled foods, obesity and ageing. People with Helicobacter infections are also highly prone to gastric cancer. Symptoms of gastric cancer may include, fatigue, feeling bloated after eating, severe heartburn and indigestion, stomach pain, persistent and unexplained vomiting and nausea, unintentional weight loss, belching, anemia, and persistent ulcer. Its medical diagnosis techniques involve upper endoscopy, imaging tests and exploratory surgery. Treatment options include surgery, chemotherapy, radiotherapy and targeted therapy.

Global gastric cancer market is conspicuous by poor prognosis, because of the indolent nature of the disease. However, better diagnostic technology and shifting treatment market from chemotherapy to targeted therapies is expected to warrant positive growth in the years ahead. Rising oncology drug spending, ageing population, increasing obese population and rising global male population are expected to drive this growth. Certain trends in the global gastric cancer market include, a healthy pipeline of combinations targeted therapies, shifting focus towards molecular targeted therapies, and keen interest in eradication H. Pylori infection across the globe. The market is however, afflicted by certain challenges like low penetration of new targeted therapies and lack of reimbursement of cancer drugs.

The report provides an overview of the entire market through global and regional analysis. Prevalence and market value of gastric cancer across the globe and that of its various types and stages including advanced, her2 positive, stage III and metastatic gastric cancer have been analyzed.


1. Market Overview
1.1 Introduction
1.2 Types
Table 1: Different Types of Gastric Cancer
1.3 Stages
1.4 Causes & Prevention
1.5 Diagnosis
1.5.1 Symptoms
1.5.2 Medical Diagnosis
1.6 Treatment Options
1.6.1 Surgery
1.6.2 Chemotherapy
1.6.3 Radiotherapy
1.6.4 Targeted Therapy
Table A: Types of Targeted Therapies
2. Global Market
2.1 Global Gastric Cancer Market by Prevalence
Table 2: Global Gastric Cancer Market by Prevalence (2015-2020E)
2.2 Global Advanced Gastric Cancer Market by Value
Table 3: Global Advanced Gastric Cancer Market by Value (2015-2020E)
3. Regional Markets
3.1. The U.S.
3.1.1 The U.S. Gastric Cancer Market by Prevalence
Table 4: The U.S. Gastric Cancer Market by Prevalence (2015-2020E)
3.1.2 The U.S. Her 2+ Gastric Cancer Prevalence
Table 5: Prevalence of Her 2+ Gastric Cancer in the U.S. (2015-2020E)
3.1.3 The U.S. Stage III Gastric Cancer Prevalence
Table 6: Prevalence of Stage III Gastric Cancer in the U.S. (2015-2020E)
3.1.4 The U.S. Advanced Gastric Cancer Market by Prevalence
Table 7: The U.S. Advanced Gastric Cancer Market by Prevalence (2015-2020E)
3.1.5 The U.S. Advanced Gastric Cancer Market by Value
Table 8: The U.S. Advanced Gastric Cancer Market by Value (2015-2020E)
3.1.6 The U.S. Metastatic Gastric Cancer Prevalence
Table 9: Prevalence of Metastatic Gastric Cancer in the U.S. (2015-2020E)
3.2 The European Union
3.2.1 The EU Her 2+ Gastric Cancer Prevalence
Table 10: Prevalence of Her2+ Gastric Cancer in the EU (2015-2020E)
3.2.2 The EU Stage III Gastric Cancer Prevalence
Table 11: Prevalence of Stage III Gastric Cancer in the EU (2015-2020E)
3.2.3 The EU Metastatic Gastric Cancer Prevalence
Table 12: Prevalence of Metastatic Gastric Cancer in the EU (2015-2020E)
3.3 The EU5
3.3.1 The EU5 Gastric Cancer Market by Prevalence
Table 13: The EU5 Gastric Cancer Market by Prevalence (2015-2020E)
3.3.2 The EU5 Advanced Gastric Cancer Market by Prevalence
Table 14: The EU5 Advanced Gastric Cancer Market by Prevalence (2015-2020E)
3.3.3 The EU5 Advanced Gastric Cancer Market by Value
Table 15: The EU5 Advanced Gastric Cancer Market by Value (2015-2020E)
3.4 Japan
Table 16: Japan Gastric Cancer Market by Prevalence (2015E-2020E)
3.4.2 Japan Advanced Gastric Cancer Market by Prevalence
Table 17: Japan Advanced Gastric Cancer by Prevalence (2015-2020E)
3.4.3 Japan Advanced Gastric Cancer Market by Value
Table 18: Japan Advanced Gastric Cancer Market by Value (2015-2020E)
4. Market Dynamics
4.1 Growth Drivers
4.1.1 Rising Spending on Targeted Cancer Therapies
Table 19: Global Targeted Therapies Spending (2010-2015E)
4.1.2 Rising Oncology Drug Spending
Table 20: Global Oncology Drug Spending by Region (2010-2015E)
4.1.3 Rising Ageing Population
Table 21: Global Population Over 50 Years of Age (2010-2015E)
4.1.4 Increasing Obese Population
Table 22: Global Obese Population (2010-2015E)
4.1.5 Rising Global Male Population
Table 23: Global Male Population (2010-2015E)
4.1.6 Rising Cigarette Consumption
Table 24: Global Cigarettes Consumption (1910-2014)
4.2 Trends
4.2.1 Combinations Targeted Therapies under Development
Table 25: Combination Regimen Launches in Oncology (2014-2020E)
4.2.2 Targeted Agents in Development by Pathways
Table 26: Pipeline of Targeted Agents in Development by Pathways (2015)
4.2.3 Shifting Focus towards Molecular Targeted Therapies
4.2.4 H. Pylori Eradication
4.3 Challenges
4.3.1 Low Penetration of New Targeted Therapies
Table 27: Penetration of New Targeted Therapies by Country (2015)
4.3.2 Lack of Reimbursement of Cancer Drugs
Table 28: Cancer Drugs Reimbursement Status by Country (2015E)
5. Competitive Landscape
5.1 Global Cancer Market
5.1.1 Top Cancer Drugs Revenue Comparison
Table B: Top Cancer Drugs by Revenue (2015)
5.1.2 Potential Combination Therapy Launches
Table 29: Potential Combination Therapy Launches by Company (2021E)
5.2 Global Gastric Cancer Market
5.2.1 Top Companies by Revenue
Table 30: Gastric Cancer - Top Companies Revenue Comparison (2015)
5.2.2 Top Companies by Revenue Growth
Table 31: Gastric Cancer - Revenue Growth Comparison by Company (2015)
5.2.3 Gastric Cancer Products under Clinical Trial
Table C: Gastric Cancer Pre-Treated Clinical Trials Comparison
Table D: Gastric Cancer Treatment Naive Clinical Trials
6. Company Profiles
6.1 Roche Holdings AG
6.1.1 Business Overview
Table 32: Roche Holdings AG Revenue by Segment (2015)
6.1.2 Financial Overview
Table 33: Roche Holdings AG Revenue and Net Income (2011-2015)
6.1.3 Business Strategies
6.2 Bristol Myers Squibb
6.2.1 Business Overview
Table 34: Bristol Myers Revenue by Region (2015)
6.2.2 Financial Overview
Table 35: BMY Revenue and Net Income (2011-2015)
6.2.3 Business Strategies
6.3 Merck & Co. Inc.
6.3.1 Business Overview
Table 36: Merck & Co. Inc. Revenue by Segment (2015)
6.3.2 Financial Overview
Table 37: Merck & Co. Inc. Revenue and Net Income (2011-2015)
6.3.3 Business Strategies
6.4 AstraZeneca Plc.
6.4.1 Business Overview
Table 38: AstraZeneca Revenue by Region (2015)
6.4.2 Financial Overview
Table 39: AstraZeneca Revenue and Net Income (2011-2015)
6.4.3 Business Strategies

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report